CSL Limited (OTCMKTS:CSLLY) Short Interest Up 43.7% in April

CSL Limited (OTCMKTS:CSLLY - Get Free Report) was the recipient of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 18,100 shares, an increase of 43.7% from the March 31st total of 12,600 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average trading volume of 304,900 shares, the short-interest ratio is presently 0.1 days.

CSL Trading Up 3.1 %

Shares of OTCMKTS:CSLLY traded up $2.50 during trading on Friday, hitting $83.00. 45,791 shares of the stock were exchanged, compared to its average volume of 95,507. CSL has a 12-month low of $70.22 and a 12-month high of $109.00. The company has a fifty day moving average price of $78.70 and a two-hundred day moving average price of $85.48. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.18 and a quick ratio of 0.97.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group raised shares of CSL to a "strong-buy" rating in a research note on Thursday, January 16th.

CSL Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.